This information provides answers to some common questions about VIEKIRA PAK and VIEKIRA PAK-RBV. It does not replace the advice given by your doctor, nurse or pharmacist.The doctor who prescribes VIEKIRA PAK for you is referred to in the following pages as your Hep C doctor. Please ask your Hep C doctor any questions about your treatment.

Please also refer to the Consumer Medicines Information (CMI) available on Medsafe for VIEKIRA PAK or VIEKIRA PAK-RBV, or from your pharmacist.




VIEKIRA PAK is a treatment for hepatitis C (Hep C) for a specific type of the hepatitis C virus (HCV) known as Genotype 1. The Hep C virus infects and damages liver cells.

VIEKIRA PAK is used to treat chronic hepatitis C in adults, including those with a form of cirrhosis (severe scarring of the liver) causing mild liver impairment; this is also called ‘compensated’ cirrhosis (Child-Pugh A).

VIEKIRA PAK is a combination medicine which means it includes three medicines known as ‘direct-acting antivirals’ (DAAs) that fight the Hep C virus in different ways.


For some types of patients, ribavirin (RBV) is added to VIEKIRA PAK to maximise its effectiveness.